PF-Atlas › Clinical Trials › NCT06149260

Subcutaneous Semaglutide in Systemic Scleroderma

Semaglutide Pen Injector · Phase 1

Registry ID
NCT06149260
Phase
Phase 1
Status
Unknown
Drug / intervention
Semaglutide Pen Injector
Sponsor
Second Xiangya Hospital of Central South University
Start
2024-02-29
Enrollment
10
Locations
1

About this trial

This trial will study the safety and efficacy of subcutaneous semaglutide for the treatment of Systemic Sclerosis

View NCT06149260 on ClinicalTrials.gov →

Explore related

All Semaglutide Pen Injector trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT06149260 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.